SJF-0628

mut. BRAF sel. heterobifunctional degrader

efficacy in xenograft at 50 mg/kg IP BID

VHL-based degrader from vemurafenib

Nat. Comm., Feb. 10, 2021

Yale University, New Haven, CT

13. The Yale BRAF-targeting PROTAC SJF-0628 is a VHL-based heterobifunctional degrader with in vivo activity in a xenograft model (50 mg/kg BID IP). Though mutant BRAF is a well-validated…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks